I am an academic medical oncologist with clinical (MBBS, FRACP) and research interests in neuro-oncology and early phase clinical trials.  In addition to recently submitting my PhD, I currently hold a consultant oncologist position at the Alfred Hospital as the Head of Molecular Oncology and Rare Cancers.  Despite being an early-career researcher, I have already made significant original contributions to my research field (27 peer reviewed papers, ten as first author and two as senior author) including publishing a large series on clinical correlates of PD-L1 immunohistochemistry in non-small cell lung cancer, a Cochrane meta-analysis on anti-angiogenic therapy in glioblastoma, a number of reports demonstrating novel therapeutic approaches in rarer brain tumours, as well as a range of research contributing in the field of early drug development including being first author of a first-in-human study of a novel BET inhibitor, the identification of a number of clinical relevant biomarkers in early phase trials and novel computational approaches to drug repurposing.  I have established a number of international collaborations over the course of this research and have ongoing projects related to my PhD which I expect to come to fruition in the near future.

After finishing formal training in 2015, I have completed a two-year fellowship at the Institute of Cancer Research/Royal Marsden Hospital drug development unit under the supervision of Professor Johann de Bono. During this fellowship, in addition to being a sub-investigator on a large number of early phase and first-in-human trials, I was the senior clinical fellow, was primary fellow in charge of the molecular characterisation program and actively participated in the development of clinical trials including concept design, pitching investigator initiated trials, protocol writing and development of risk mitigation plans.  Subsequent to completion of this fellowship, I have submitted my PhD in the Shackleton laboratory, having developed bench skills in tissue culture, cloning, lentiviral transduction, CRISPR, working with immunosuppressed mouse models, flow cytometry and other standard molecular biology techniques and statistical techniques. I believe that developing these foundational laboratory skills, in addition to my strong background in early-phase clinical trials, is a unique set of skills that provides a strong platform for developing as a clinician scientist in the translational space. Clinically, I have done a fellowship in neuro-oncology and continue to manage neuro-oncology patients in my clinical practice.